Shots:

• Kite will receive a one-time upfront to purchase Kite’s individualized solid tumor neoantigen TCR discovery platform- R&D & clinical manufacturing facility in Gaithersburg. The Transaction is expected to be close at the end of Jul’21
• BioNTech will use the Kite’s facility to support clinical trials in the US & will add its cell therapy manufacturing facility in Idar-Oberstein- Germany
• The agreement will strengthen BioNTech’s cell therapy pipeline by accelerating individualized solid tumor Neoantigen TCR cell therapy research and development program and adds the manufacturing footprint in North America

Ref:  Globenewswire | Image: Money Control